DRG Market Assessment reports

Fibromyalgia is a chronic condition characterized by pain and tenderness. The primary goal of treatment is to reduce the pain, for which multiple well-established treatment options are available,…

Decision Resources Group anticipates the next ten years to be an exciting time in the type 1 diabetes (T1D) space as the number of treatment options continues to grow. Existing agents fail to…

KEY BENEFITS AND USES Pinpoint current drug positioning and uptake in one snapshot to facilitate forecasting. Drill down into physicians’ treatment sequences and understand who the…

Nonalcoholic steatohepatitis (NASH) has the potential to be a large and lucrative market for pharmacotherapies owing to the lack of approved agents and the disease’s prevalence. The body of…

Pharmacotherapy for adult asthma has two main goals: address underlying airway inflammation and promote bronchodilation. Two types of therapy are used to achieve these goals—maintenance therapy (…

Hydroxychloroquine, corticosteroids, and conventional immunosuppressants are the mainstay of treatment for systemic lupus erythematosus (SLE), a chronic, complex autoimmune disease affecting…

MARKET OUTLOOK Atopic dermatitis (AD) is a chronic inflammatory skin disease marked by pruritus, eczema, and, in some cases, disrupted sleep and poor quality of life. Topical agents (e.g.,…

Metformin and the sulfonylureas are the most heavily prescribed drugs in T2D and dominate the early lines of therapy prior to disease progression, which requires insulin replacement. The emergence…

MARKET OUTLOOK Conventional therapies (5-ASAs, corticosteroids) are typically used to treat mild to moderate pediatric ulcerative colitis (UC), whereas tumor necrosis factor-alpha (TNF-α)…

Xeljanz is the first-in-class JAK inhibitor approved for psoriatic arthritis (PsA) and the only other oral targeted therapy besides Celgene’s PDE-4 inhibitor, Otezla, approved for this indication…

Allergic rhinitis is a chronic immunoglobulin E-mediated respiratory response to environmental allergens. It is typically treated with intranasal corticosteroids, followed by antihistamines, mast…

Alongside putative disease-modifying therapies, the late-phase pipeline in Alzheimer’s disease (AD) features several therapies for the treatment of behavioral symptoms in AD. Symptoms such as…